S &p امتدح هذا السهم وهو سهمه لهذا الأسبوع لكن؟

الموضوع في 'السوق الأمريكي للأوراق الماليه' بواسطة أبو وليد, بتاريخ ‏8 فبراير 2002.

  1. أبو وليد

    أبو وليد عضو جديد

    التسجيل:
    ‏9 نوفمبر 2001
    المشاركات:
    147
    عدد الإعجابات:
    0
    في الديتك جاءت توصية S & P هذا الأسبوع لسهم تربوز TRIPOS وهذه الرسالة وصلت لكل المشتركين بالداتك ..وذكر أن الشركة لها مستقبل جيد وأنها تتعاون مع شركات كبرى في العلوم الحيوية والطبية المختلفة مثل فايزر الخ ولها أبحاث تقنية متقدمة وهلم جرا كما يظهر في التقرير التالي ..


    لكن في موقع آخر وجدت أن شركة LION قد باعت مؤخرا أكثر من 800,000 سهم من تربوز


    فمن يعرف عن الشركة شيئا فليذكره مشكورا


    Formula for Growth

    S&P says drug discovery services provider Tripos is ready to ride the boom in pharmaceutical contract research
    Standard&Poor's Focus Stock of the Week is Tripos Inc. (TRPS), a leading provider of integrated discovery software products, software consulting services, and discovery research services to the pharmaceutical, biotechnology, agrochemical, and other life sciences industries. Tripos carries S&P's highest investment recommendation, 5 STARS, or strong buy.

    Tripos' offerings help its clients outsource their research and discovery activities as a means to reduce their product discovery costs and time-to-market. That's particularly important for customers such as pharmaceutical companies who are under pressure from patent expiration and generic drug competition.

    The contract research market is expected by S&P to expand to as much as $15 billion in sales by 2004, and Tripos is well-positioned to capitalize on this opportunity. Case in point: The company last month announced a contract with Pfizer totaling over $100 million in potential revenue over the next four years to provide it with its proprietary discovery research, software licenses, and software research products and services.

    FAVORABLE TRENDS. S&P's positive outlook for the company stems largely from our belief that long-term industry trends underpin demand for the company's products and unique expertise. In fact, the success of companies in the pharmaceutical and biotechnology industries largely depends upon their ability to identify new chemical compounds with targeted properties that can be brought to market rapidly and on a cost-effective basis.

    Currently, the discovery and development of a blockbuster drug takes about 8-12 years, and costs an average of $500 million per drug. By reducing the time-to-market, pharmaceutical companies can generate substantial amounts of additional profits before their product's exclusivity patent expires and generic drug makers move in to take market share.

    In addition, in the search for biological activity, many companies have implemented high-throughput screening laboratories for the rapid analysis of large numbers of compounds. High-volume screening has resulted in an unprecedented information explosion of chemical data that need to be processed, managed, analyzed and used for decision making. Repositories for this data must be built and the data must be mined and shared -- much of the time across multi-national, cross-corporate boundaries.

    UNIQUE PRODUCTS. Tripos, through its demonstrated ability to integrate chemical data and information technologies, provides the life sciences industry with a solid opportunity to speed the discovery process and reduce costs. The company's foundation is built on its expertise and reputation as a cutting-edge molecular design software provider. Using sophisticated cheminformatics it designs and produces drug-like compounds for screening using proven, reliable and patented methods. Thus, scientists avoid costly laboratory synthesis for chemical compounds not likely to be effective.

    But it's not just software: Tripos offers an integrated suite of innovative, knowledge-based discovery products and services that accelerate the discovery process for customers. Its integration of software tools, related software support, customized information management services, designed chemical compound libraries and discovery research services is a unique and unprecedented approach to solving discovery research problems.

    BRIGHT OUTLOOK. Our bullishness on the shares is further confirmed by the company's recent announcements of strategic alliances with major pharmaceutical companies -- like Pfizer, AstraZeneca, Bristol Myers-Squibb and Novo Nordisk. Tripos also has deals with smaller players such as Arena and Cyprotex. Although it has been working with Pfizer for more than a decade, the January, 2002, contract is particularly significant because of its size and, even more importantly, because it validates the company's drug discovery technology and knowledge and raises its visibility.

    The Pfizer deal is also important because it could also open up the possibility of future, more lucrative collaborations where Tripos would provide an optimized lead -- a compound that Tripos has reviewed and pre-screened and that has a high probability of curing a certain disease when tested in animals and humans -- and not just a number of pure compounds. We believe the company will be able to secure more drug discovery collaborations as the Pfizer's partnership will be used as a model for deals with other companies.

    In addition to the deal with Pfizer, Tripos entered 2002 with continuing contracts with major pharmaceutical firms and a strong pipeline in all business areas. We at S&P project revenues of $62.2 million and earnings per share of $0.67 for 2002. In 2003 we see revenues of $80.8 million and EPS of $0.94.

    Tripos does not come cheap at 46X our 2002 estimate of $0.67, but S&P believes that the shares represent an excellent growth opportunity for aggressive investors due to its projected annual earnings growth rate of over 30% for the foreseeable future. Moreover, Tripos is already profitable and generates positive free cash flows, a rarity in the life sciences sector. Assuming high but decelerating growth in free cash flow over the next 15 years, S&P's discounted cash flow model points to a price target of $40, which represent a potential price appreciation of about 33% from current levels








    -----------------

    وهنا تقرير بيع lion

    LION Bioscience Announces Sale of its Shareholdings in Tripos Inc.; No Strategic Need for Tripos Shareholding After Successful Completion of NetGenics Acquisition
    THURSDAY, FEBRUARY 07, 2002 9:03 AM
    - BusinessWire

    HEIDELBERG, Germany & CAMBRIDGE, Mass., Feb 7, 2002 (BW HealthWire) -- LION bioscience AG (LIO) announced today that it has sold all of its shareholdings in Tripos Inc. Total net proceeds to LION from the entire transaction, came to US$22.5 million.

    LION had purchased 409,091 shares of convertible preferred stock from Tripos in early February 2000 for a total purchase price of US$9 million. In late January 2002, LION converted these shares into 818,192 shares of Tripos common stock. At this time, Tripos paid LION an accrued dividend on these shares of convertible preferred stock of more than $890,000. On February 7, 2002, LION sold all of its shares of Tripos common stock. The net proceeds to LION from this sale were approximately US$21.6 million.

    "Following our recent acquisition of NetGenics, LION now has all of the elements for delivering an industry-leading data and application integration platform for the Life Sciences industry. As a result, we no longer consider our investment in Tripos to be of strategic value to LION. Therefore we have decided to sell our shareholding in Tripos," said Dr. Friedrich von Bohlen, CEO of LION bioscience. "But of course, LION is committed to continuing its collaboration with Tripos in providing Bayer AG with a pharmacophore informatics platform to accelerate Bayer's drug discovery activities." LION is the project leader of this collaboration.


    About LION bioscience AG:

    LION bioscience (http://www.lionbioscience.com) provides proven information and knowledge management solutions to significantly improve life science R&D performance and productivity. These solutions integrate all R&D disciplines, spanning from genomics to early and late discovery through clinical trials. LION applies these solutions for its internal drug discovery program in the field of nuclear receptors with the goal to out-license specific databases, polymorphism marker panels, and validated targets and leads.

    Founded in 1997, LION has 540 employees, with headquarters in Heidelberg, Germany, and subsidiaries in Cambridge, UK, Cambridge, MA, USA and San Diego, CA, USA. To date, LION has established partnerships with leading life science companies, including Aventis, Bayer, Boehringer Ingelheim, Celera, DuPont, GlaxoSmithKline, Janssen, Merck Inc., Nestle, Novartis, Paradigm Genetics, Pharmacia & Upjohn, Roche, Sumitomo Pharmaceuticals and Tripos.